# Immunotherapy With Racotumomab in Advanced Lung Cancer

> **NCT01460472** · PHASE3 · UNKNOWN · sponsor: **Recombio SL** · enrollment: 1082 (estimated)

## Conditions studied

- NSCLC
- Lung Cancer, Non-small Cell

## Interventions

- **BIOLOGICAL:** Racotumomab
- **OTHER:** Best Support Treatment

## Key facts

- **NCT ID:** NCT01460472
- **Lead sponsor:** Recombio SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 1082 (ESTIMATED)
- **Last updated:** 2016-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460472, "Immunotherapy With Racotumomab in Advanced Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01460472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*